Search - tctmd.com

Displaying 601 - 620 of 997

Sort: Relevancy | Date

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

News Conference News EAS 2018

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

LPA Variants Linked With CHD Events in Statin-Treated Patients

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Daily News

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Michael O'Riordan

April 16, 2018

News Daily News

Childhood Obesity Can Affect Cardiovascular Risk Even If Resolved by Adulthood

Yael L. Maxwell

April 11, 2018

News Daily News

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Michael O'Riordan

April 09, 2018

News Daily News

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

Shelley Wood

April 06, 2018

News Daily News

Physical Activity Conversations With Patients Need to Be Routine, AHA Says

Todd Neale

April 06, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

Shelley Wood

April 02, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

Podcast Heart Sounds

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

Advertisement

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Alirocumab Price Slashed in Deal With Express Scripts

LPA Variants Linked With CHD Events in Statin-Treated Patients

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Childhood Obesity Can Affect Cardiovascular Risk Even If Resolved by Adulthood

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Costs of Atherosclerotic CVD Cripple Low-Income Families, Even With Insurance

Physical Activity Conversations With Patients Need to Be Routine, AHA Says

TCTMD’s Top 10 Most Popular Stories for March 2018

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Top Stories in Cardiology, March 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content